AR111176A1 - Derivados pirazol[1,5-a]pirimidina sustituidos con alicíclicos farmacológicamente activos - Google Patents
Derivados pirazol[1,5-a]pirimidina sustituidos con alicíclicos farmacológicamente activosInfo
- Publication number
- AR111176A1 AR111176A1 ARP180100580A ARP180100580A AR111176A1 AR 111176 A1 AR111176 A1 AR 111176A1 AR P180100580 A ARP180100580 A AR P180100580A AR P180100580 A ARP180100580 A AR P180100580A AR 111176 A1 AR111176 A1 AR 111176A1
- Authority
- AR
- Argentina
- Prior art keywords
- 6alkyl
- halogen
- 6alkoxy
- halo
- compounds
- Prior art date
Links
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 230000003281 allosteric effect Effects 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 150000004677 hydrates Chemical class 0.000 abstract 2
- 239000002207 metabolite Substances 0.000 abstract 2
- 229940002612 prodrug Drugs 0.000 abstract 2
- 239000000651 prodrug Substances 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 1
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 1
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 abstract 1
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 abstract 1
- -1 C1−6alkoxy-C1−6alkyl Chemical group 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000002483 medication Methods 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 abstract 1
- 150000003230 pyrimidines Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 239000011593 sulfur Substances 0.000 abstract 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 abstract 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Derivados de pirazol[1,5-a]pirimidina de la fórmula (1) o sales farmacéuticamente aceptables, metabolitos biológicamente activos, profármacos, racematos, enantiómeros, diastereómeros, solvatos e hidratos de los mismos que sirven como moduladores alostéricos positivos del receptor del GABAB. Proceso para producir dichos compuestos. Composiciones farmacéuticas que comprenden dichos compuestos, opcionalmente en combinación con dos o más agentes terapéuticos diferentes, y con el uso de dichos compuestos en métodos de tratamiento de enfermedades y condiciones mediadas y moduladas por el mecanismo alostérico positivo del receptor GABAB. Método para elaborar medicamentos que son de utilidad en el tratamiento de dichos trastornos. Reivindicación 1: Un compuesto, caracterizado porque es de la fórmula (1), R¹ y R² se seleccionan independientemente entre un átomo de hidrógeno, halógeno, C₁₋₆alquilo, halo-C₁₋₆alquilo; R³ es un átomo de hidrógeno, halógeno, un grupo C₁₋₆alquilo, ciano; R⁴ es C₁₋₆alquilo; R⁵ es C₁₋₆alquilo opcionalmente sustituido con un átomo de halógeno o átomos de halógeno, un grupo C₃₋₅cicloalquilo; C₃₋₅cicloalquil-C₁₋₆alquilo, dialquilamino, C₁₋₆alcoxi, C₁₋₆alcoxi-C₁₋₆alquilo, C₁₋₆alquiltio, tetrahidrofuranilo, tetrahidrofuranil-C₁₋₆alquilo, tetrahidropiranilo, tetrahidropiranilo-C₁₋₆alquilo; o R⁴ y R⁵ juntos forman un anillo de 3 a 7 miembros saturados no sustituidos o sustituidos por uno o más C₁₋₃alquilo, C₁₋₃alcoxi, halo-C₁₋₃alquilo, C₁₋₃alquilcarbonilo, donde los miembros del anillo se seleccionan entre el grupo que consiste en carbono, nitrógeno, oxígeno y azufre; R⁶ es un átomo de hidrógeno, halógeno o un grupo C₁₋₆alquilo, hidroxilo, C₁₋₆alcoxi, C₁₋₆alcoxi-C₁₋₆alquilo, halo-C₁₋₆alquilo, amino; o sales farmacéuticamente aceptables, metabolitos biológicamente activos, profármacos, racematos, enantiómeros, diastereómeros, solvatos e hidratos de los mismos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU1700108A HU231058B1 (hu) | 2017-03-13 | 2017-03-13 | Gyógyászatilag hatékony aliciklusos-szubsztituált pirazolo[1,5-a]pirimidin származékok |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR111176A1 true AR111176A1 (es) | 2019-06-12 |
Family
ID=89992389
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP180100580A AR111176A1 (es) | 2017-03-13 | 2018-03-13 | Derivados pirazol[1,5-a]pirimidina sustituidos con alicíclicos farmacológicamente activos |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US11026946B2 (es) |
| EP (1) | EP3596080B1 (es) |
| JP (1) | JP7153662B2 (es) |
| KR (1) | KR20190127779A (es) |
| CN (1) | CN110431142A (es) |
| AR (1) | AR111176A1 (es) |
| AU (1) | AU2018235266B2 (es) |
| BR (1) | BR112019018843A2 (es) |
| CA (1) | CA3056185A1 (es) |
| CL (1) | CL2019002601A1 (es) |
| CO (1) | CO2019010120A2 (es) |
| CY (1) | CY1124708T1 (es) |
| DK (1) | DK3596080T3 (es) |
| EA (1) | EA038756B1 (es) |
| EC (1) | ECSP19072975A (es) |
| ES (1) | ES2893824T3 (es) |
| GE (1) | GEP20217256B (es) |
| HR (1) | HRP20211850T1 (es) |
| HU (2) | HU231058B1 (es) |
| IL (1) | IL268923A (es) |
| LT (1) | LT3596080T (es) |
| MX (1) | MX2019011000A (es) |
| MY (1) | MY195262A (es) |
| PE (1) | PE20191646A1 (es) |
| PH (1) | PH12019501968A1 (es) |
| PL (1) | PL3596080T3 (es) |
| PT (1) | PT3596080T (es) |
| RS (1) | RS62533B1 (es) |
| SG (1) | SG11201907864YA (es) |
| SI (1) | SI3596080T1 (es) |
| UA (1) | UA124783C2 (es) |
| WO (1) | WO2018167630A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU231057B1 (hu) | 2017-03-13 | 2020-04-28 | Richter Gedeon Nyrt | Gyógyászatilag hatékony aril-szubsztituált pirazolo[1,5-a]pirimidin származékok |
| PL3595665T3 (pl) | 2017-03-13 | 2025-01-13 | Lundbeck La Jolla Research Center, Inc. | Podwójne inhibitory magl i faah |
| TWI901650B (zh) | 2020-03-26 | 2025-10-21 | 匈牙利商羅特格登公司 | 啶及吡啶并〔３，４－ｃ〕嗒衍生物 |
| IL300208A (en) | 2020-08-05 | 2023-03-01 | Richter Gedeon Nyrt | Pharmacologically active heterocyclic substituted pyrazolo[5,1-a]pyrimidine derivatives |
| HU231691B1 (hu) | 2021-09-29 | 2025-10-28 | Richter Gedeon Nyrt | GABAA ALFA5 receptor modulátor hatású biciklusos aminszármazékok |
| CN115872095A (zh) * | 2022-11-28 | 2023-03-31 | 南通三鑫车灯配件有限公司 | 一种汽车车灯反光罩的生产线流转装置 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005094828A1 (en) | 2004-03-02 | 2005-10-13 | F. Hoffmann-La Roche Ag | 4- (sulfanyl-pyrimidin-4-ylmethyl) -morpholine derivatives and related compounds as gaba receptor ligands for the treatment of anxiety, depression and epilepsy |
| GB0512844D0 (en) | 2005-06-23 | 2005-08-03 | Novartis Ag | Organic compounds |
| KR100753017B1 (ko) * | 2006-05-25 | 2007-08-30 | 한국화학연구원 | 7-(3,4-디알콕시페닐)-피라졸로[1,5-ａ]피리미딘 화합물을포함하는 관절염, 아토피 피부염, 백혈병을 포함한 암 및알쯔하이머, 우울증 또는 기억력 감소 등의 뇌질환의 치료및 예방을 위한 약제학적 조성물 |
| US8461163B2 (en) | 2008-03-31 | 2013-06-11 | Takeda Pharmaceutical Company Limited | Substituted N-(pyrazolo[1,5-a]pyrimidin-5-yl)amides as inhibitors of apoptosis signal-regulating kinase 1 |
| TWI648281B (zh) | 2013-10-17 | 2019-01-21 | 日商安斯泰來製藥股份有限公司 | 含硫二環式化合物 |
| US9828381B2 (en) * | 2015-04-20 | 2017-11-28 | AbbVie Deutschland GmbH & Co. KG | Substituted pyrazolopyrimidines and method of use |
| JP2018199623A (ja) | 2015-10-22 | 2018-12-20 | 大正製薬株式会社 | 含窒素縮合複素環化合物 |
| HU231057B1 (hu) | 2017-03-13 | 2020-04-28 | Richter Gedeon Nyrt | Gyógyászatilag hatékony aril-szubsztituált pirazolo[1,5-a]pirimidin származékok |
-
2017
- 2017-03-13 HU HU1700108A patent/HU231058B1/hu not_active IP Right Cessation
-
2018
- 2018-03-12 CA CA3056185A patent/CA3056185A1/en active Pending
- 2018-03-12 DK DK18713016.6T patent/DK3596080T3/da active
- 2018-03-12 MX MX2019011000A patent/MX2019011000A/es unknown
- 2018-03-12 PT PT18713016T patent/PT3596080T/pt unknown
- 2018-03-12 EP EP18713016.6A patent/EP3596080B1/en active Active
- 2018-03-12 US US16/493,453 patent/US11026946B2/en active Active
- 2018-03-12 HU HUE18713016A patent/HUE056562T2/hu unknown
- 2018-03-12 HR HRP20211850TT patent/HRP20211850T1/hr unknown
- 2018-03-12 CN CN201880017859.XA patent/CN110431142A/zh active Pending
- 2018-03-12 AU AU2018235266A patent/AU2018235266B2/en not_active Ceased
- 2018-03-12 KR KR1020197028833A patent/KR20190127779A/ko not_active Ceased
- 2018-03-12 ES ES18713016T patent/ES2893824T3/es active Active
- 2018-03-12 BR BR112019018843A patent/BR112019018843A2/pt not_active Application Discontinuation
- 2018-03-12 PE PE2019001773A patent/PE20191646A1/es unknown
- 2018-03-12 SG SG11201907864YA patent/SG11201907864YA/en unknown
- 2018-03-12 SI SI201830495T patent/SI3596080T1/sl unknown
- 2018-03-12 UA UAA201910328A patent/UA124783C2/uk unknown
- 2018-03-12 EA EA201992127A patent/EA038756B1/ru unknown
- 2018-03-12 RS RS20211334A patent/RS62533B1/sr unknown
- 2018-03-12 LT LTEPPCT/IB2018/051599T patent/LT3596080T/lt unknown
- 2018-03-12 PL PL18713016T patent/PL3596080T3/pl unknown
- 2018-03-12 WO PCT/IB2018/051599 patent/WO2018167630A1/en not_active Ceased
- 2018-03-12 MY MYPI2019004947A patent/MY195262A/en unknown
- 2018-03-12 JP JP2019549366A patent/JP7153662B2/ja active Active
- 2018-03-12 GE GEAP201815192A patent/GEP20217256B/en unknown
- 2018-03-13 AR ARP180100580A patent/AR111176A1/es unknown
-
2019
- 2019-08-26 IL IL26892319A patent/IL268923A/en unknown
- 2019-08-27 PH PH12019501968A patent/PH12019501968A1/en unknown
- 2019-09-12 CL CL2019002601A patent/CL2019002601A1/es unknown
- 2019-09-18 CO CONC2019/0010120A patent/CO2019010120A2/es unknown
- 2019-10-10 EC ECSENADI201972975A patent/ECSP19072975A/es unknown
-
2021
- 2021-11-08 CY CY20211100964T patent/CY1124708T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR111176A1 (es) | Derivados pirazol[1,5-a]pirimidina sustituidos con alicíclicos farmacológicamente activos | |
| CO2023003282A2 (es) | Nuevos derivados de psilocina que tienen propiedades de profármaco | |
| ECSP22077299A (es) | Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades asociadas con modulación del pi3k | |
| AR115993A2 (es) | Composiciones de pirrolopirrol como activadores de piruvato quinasa (pkr) | |
| AR113818A2 (es) | Pirazolo-quinazolinas como inhibidores de proteína quinasa | |
| MX420195B (es) | Compuestos macrocíclicos como agonistas de sting y métodos y usos de los mismos | |
| AR064608A1 (es) | Derivados de pirazolo-quinazolina sustituidos, composiciones farmaceuticas que los contienen. proceso para su preparacion y uso de los mismos como agentes anticancer. | |
| AR110782A1 (es) | Derivados de tirosinamida como inhibidores de rho-quinasa | |
| AR100713A1 (es) | Derivados de amida de compuestos de 1-oxa-4,9-diazaespiro undeceno que tienen actividad multimodal contra el dolor | |
| AR079205A1 (es) | Morfolinotiazoles como moduladores alostericos positivos alfa 7 | |
| AR105522A1 (es) | Derivados de amida sustituida que tienen actividad multimodal contra el dolor | |
| AR087915A1 (es) | N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1 | |
| NI201300072A (es) | Derivados de heteroarilo como moduladores nachr alfa 7 | |
| AR100715A1 (es) | Derivados de alquilo de compuestos 1-oxa-4,9-diazaespiro undeceno que tienen actividad multimodal contra el dolor | |
| AR111272A1 (es) | Derivados pirazol[1,5-a]pirimidina sustituidos con arilo farmacológicamente activos | |
| AR100714A1 (es) | Derivados de alquilo y arilo de compuestos de 1-oxa-4,9-diazaespiro undecano que tienen actividad multimodal contra el dolor | |
| PE20201280A1 (es) | Amidas de imidazopiridina sustituidas y su uso | |
| CL2023000352A1 (es) | Derivados de pirazolo[1,5-a]pirimidina sustituidos con heterocíclicos farmacológicamente activos | |
| AR045156A1 (es) | Derivados de 5-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos | |
| AR047531A1 (es) | Derivados 1h-tieno(2,3-c)pirazol utiles como inhibidores de quinasa | |
| EA202190857A1 (ru) | Бициклические производные как модуляторы 5 рецепторов gabaa | |
| ECSP22007557A (es) | Un derivado de tetrahidroisoquinolina sustituido como modulador alostérico positivo de d1 | |
| AR108535A1 (es) | Derivados de tetrahidropirano y tiopirano que tienen actividad multimodal contra el dolor | |
| CO2017011511A2 (es) | Derivados de indol | |
| AR120170A1 (es) | Derivados de 2-azaspiro[3,4]octano como agonistas de m4 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |